Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Clinical-stage biotech innovator BioRestorative Therapies (NASDAQ:BRTX) recently announced that it is entering a new program of preclinical metabol...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.32% on an annualized basis producing an average annual return of 20...
JPMorgan Chase & Co.’s (NYSE:JPM) asset management division has reportedly secured over $500 million for a biotech venture capital fund f...
Jim Cramer has expressed his confidence in Eli Lilly and Co (NYSE:LLY), citing the company’s diverse drug portfolio and the recent endorsemen...
U.S. District Judge Karen Marston in Philadelphia is set to preside over litigation involving the popular diabetes and weight-loss drugs Ozempic, W...
With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have s...
The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk (NYSE:NVO) is leading to new product developments across various sectors. Wh...
Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its...
Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NY...
News, Short Squeeze, Breakout and More Instantly...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...
2024-07-05 05:45:00 ET With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for other treatments, it's natural for investors to assume that Nov...